Plenty of Room? On a Sunday?
You know I love science, it’s the whole reason we’re here! Something else I love? Startups and innovation. So, I said to myself: Why not try my hand at analyzing the cool science of startups I run into?
So, this is the first issue of my new series “The Deep Tech Breakdown”! The name is not final, feel free to send me suggestions. And please, let me know what you think! Do you like? What can I improve? You feedback is important to me!
But now, let’s start!
Would you keep all your DNA at room temperature, outside the freezer?
Cache DNA wants you to do it. And it’s building room-temperature nucleic acid preservation tech to make it happen. Below, everything you need to know about why it matters, their technology, and what we still don’t know!
Don’t keep this newsletter a secret: Forward it to a friend today!
Was this email forwarded to you? Subscribe here!
Cache DNA: The Breakdown
Cache DNA is building room-temperature nucleic acid preservation technology to make biotech sample storage cheaper and more reliable.
What They’re Actually Doing
Company basics
Cache DNA was founded in 2022 in San Carlos, California. The MIT spinout was originally focused on DNA data storage, it’s now positioning itself as a nucleic acid preservation platform.
The problem
Modern biotech runs on a cold chain. During my PhD, we had fridges full of proteins, DNA, and RNA. But it’s not only research labs but also clinical samples, mRNA vaccines, or organs in transit!
But freezers and fridges are expensive, energy-hungry, and inaccessible in isolated or resource-limited settings. The WHO estimates that over 25% of vaccines worldwide are wasted because of cold-chain failures!
In particular, nucleic acids degrade at room temperature through enzymatic degradation, oxidation, and hydrolysis. If we could store samples at room temperature without degradation, it would transform sample handling, reduce costs, and democratize access to biotech.
The evolution of their solution
Cache DNA has developed 3 iterations of DNA preservation chemistry (with super cool names):
V1 - “FOSSIL”: Silica-based encapsulation (published, peer-reviewed)
V2 - “RAPTOR”: Polymer-based encapsulation (published, peer-reviewed) → faster and less toxic solvents
V3 - “CRADLE”: Aqueous reagent-based stabilization (current product, proprietary chemistry) → “add-n-done” workflow.
Why it matters
If this works at scale with long-term stability, it could eliminate cold-chain dependence and transform how samples are handled in research, diagnostics, and clinical settings. And with increasing demand for sequencing in biomedicine and new sequences for designed proteins, we’ll have a lot more DNA moving around! A reliable and cheaper storage method will be essential.
The Published Technology: Fossil & Raptor
Cache DNA went through 3 generations of DNA-preserving technology.
Note: I focus on Fossil and Raptor here because their mechanisms are published and peer-reviewed, allowing a technical assessment. I discuss Cradle below!
Core Scientific Mechanism
The chemistry varies, but Fossil and Raptor work through 3 basic steps:
Charge neutralization
Free nucleic acids are highly negatively charged, and in solution, they can aggregate and precipitate because of electrostatic repulsion. Not good. Both Fossil and Raptor begin by binding nucleic acids to charged materials (silica in V1, polymers in V2) that neutralize the charges and stabilize the molecules in solution.Encapsulation and protection
Once the charges are neutralized, the nucleic acids are enclosed within a protective barrier:
- FOSSIL → A silica matrix encapsulates DNA, creating a glass-like protective cage.
- RAPTOR → A polymer coating forms a protective shellThese barriers shield nucleic acids from the primary degradation pathways at room temp:
- Enzymatic degradation: DNases and RNases are everywhere.
- Hydrolytic attack: Water-based breakdown of bonds.
- Oxidative stress: Free radicals that damage bases and the backbone.Triggered release
The protective layer isn’t permanent. When you need the preserved nucleic acids, add specific resuspension buffers that dissolve the silica or polymer matrix, releasing intact nucleic acids ready for downstream applications (PCR, sequencing, cloning, etc.)
Innovation and Scientific Novelty
Room-temp nucleic acid storage isn’t new. I mean, we’ve all used freeze-dried DNA! Thanks, IDT. And researchers have explored various chemical stabilizers (betaine, trehalose, PEG, etc.) for decades.
So, what’s new about Cache DNA?
FOSSIL’s innovation: Using silica encapsulation to create a protective microenvironment while maintaining nucleic acid accessibility. The silica provides protection and a stable, inert matrix.
RAPTOR’s innovation: Moved from hard-to-remove silica to polymer-based protection, making it easier and safer to release (no toxic solvents!) and work with preserved nucleic acids in downstream applications.
The progression (FOSSIL -> RAPTOR -> CRADLE) suggests they’re optimizing for the tradeoff between protection and ease of use. Maybe they’re responding to customer feedback that silica is hard to work with, especially in high-throughput settings!
Scientific Validation: What’s Published?
It’s an MIT spinout; you know they have a strong publication record! The team has published in peer-reviewed journals to show that their preservation methods work.
Foundational chemistry work (2021 - 2024)
Publications in Nature Materials and ACS Nano established the underlying silica encapsulation and polymer chemistry principles. They also showed that DNA survives artificial aging up to 8 months!
Validation work (2026)
Most of the validation work came out this year! It’s all focused on the silica-based technology (V1 “FOSSIL”, I guess).
NAR, Molecular Medicine: They used a small sample set of 10 genomic samples. It showed preservation quality comparable to frozen samples in Illumina sequencing, and it could be reproduced by labs in different parts of the world.
Genome Biology: Similar results for long-read Oxford Nanopore sequencing, using 3 genomes kept at room temp for 30 days.
Nature Communications: Higher-throughput setup, with 96 mock SARS-CoV-2 genomic samples! Here, the whole thing is converted into a molecular database, although they didn’t use any of their own systems. This is more of a validation of their “file retrieval” system and high-throughput capabilities of silica-based solutions.
So, there’s a strong publication record, and the silica and polymer-based systems are well-validated! I liked in particular that they tested it with different institutions. Validation beyond the founding lab is rare!
CRADLE: What We Know, and What We Don’t
Now, this is all well and good. But the thing is, Cache DNA’s current commercial product is “CRADLE”. And it seems new: I can only find announcements from June 2026!
CRADLE is described as an aqueous reagent-based stabilization system. That’s all I know! It’s focused on simplicity (“add-n-done” workflow), but the chemistry is proprietary, and I couldn’t find any publication/patent filing yet! This is normal for early-stage startups: they need to protect their IP! But it does make my life harder.
Also, it creates an interesting asymmetry.
Their current product (the one they want you to buy!) has the least amount of information available. And we have to evaluate based on the silica-based technology until they publish something.
Looking at their website, I can speculate on the reasons for this move (and I love speculating!):
Ease of use and reagent toxicity: The progression from FOSSIL -> RAPTOR -> CRADLE probably prioritized customer/market feedback. I mean, simply adding a solution to your DNA sample is easier than running a full reaction.
Manufacturing and scalability: The aqueous reagent might be easier to manufacture. And maybe it’s easier to scale, both in manufacturing and for clients?
It does leave some questions (I’m curious, you know that!):
Does it work better? Worse? We don’t know: no data yet! I would expect a shorter lifetime, but maybe it’s just the lack of details.
Is CRADLE so new that they haven’t had time to publish it yet? Are they protecting the IP?
Is it also being validated independently? It would make their case much stronger.
So, yeah, normal for a startup to protect its IP. But it’s the usual problem: scientists want to know what they’re working with!
Technical Risks: Where Could This Fail?
Honestly, their work is impressive! But science is science, right? There’s always something that might not work!
These are the potential problems I see:
Long-term stability
The longest published data I found is 8 months at room temperature. That’s long, but biotech samples might need to be stored for years! Is there some unknown degradation pathway here? For CRADLE, they recommend avoiding metal contamination and UV exposure. Is it a precaution or a hard rule? Long-term stability is the most critical unknown: if this doesn’t work, the value proposition collapses. I guess only time can answer (quite literally)!Buffer and sample compatibility
The preservation chemistry works with specific buffers and conditions. Expanding to different sample types (whole blood, cell lysates, various RNA preparations) might reveal unexpected incompatibilities. If each new application requires reformulation, scalability becomes much harder.DNA vs RNA
Related to the point above. Most of Cache’s work focuses on DNA, but they position themselves as “nucleic acid preservation”. But RNA is much less stable than DNA, especially at room temperature. If their encapsulation works for mRNA, that opens applications in vaccines and RNA therapeutics. If it doesn’t, the market could be much smaller. From their website, they’re looking into it!Quality control at scale
Real-world high-throughput means thousands of samples in parallel. That’s a lot of reagents! Your QC has to be on point and scale without flaws. Especially if the target market is clinical diagnostics or biobanks, where sample loss is expensive and ethically complicated.Industry adoption
Okay, this isn’t a science problem; it’s a market one. But still, biotech is conservative, and cold storage is incredibly entrenched. People put everything in a -80°C! Even with superior technology, switching requires revalidation of processes, retraining, and sometimes regulatory approval. Adoption could stall. Great science might help convince scientists! See, I brought it back to the science.
Competitive Landscape: From Freezers to DNAshells
There’s always someone telling you that whatever industry is going to be a bajillion dollars. In this case, the DNA & RNA banking services market is estimated to pass 14 billion dollars by 2032.
Now, the number is probably arbitrary, but I feel like the direction is right. Everyone is keeping more samples, from hospitals to research institutions and companies, and the scope has expanded.
We need DNA sequences not just for clinical samples, but for protein designs, RNA vaccines, or data storage. High-throughput pipelines are increasingly common. I think that Cache DNA originally focused on DNA data storage, but that market is still niche compared to general preservation.
Who Else Is There?
There are a few competitors in the general nucleic acid preservation space:
Traditional cold storage: Freezers and fridges. What Cache wants to replace!
Chemical stabilizers: Trehalose, betaine, and glycerol-based stabilizer approaches. Less protective than encapsulation but simpler.
Desiccation methods: Freeze-drying, vacuum-drying. Work but can damage some sample types. You might think these are old methods, but companies like 300k are working to modernize freeze-drying!
Physical encapsulation: Cache DNA isn’t alone here. EnsiliTech uses a similar silica-based technology, while Imagene has been creating sturdy DNAshells for 15+ years!
What’s best? Who knows; we haven’t seen head-to-head comparisons yet!
Are Freezer’s Days Numbered?
So, is this the end for freezers and fridges in biotech?
Probably not yet. But overall, Cache DNA has real technical achievements, and the science is solid. The main uncertainties are:
Engineering challenge → Can they produce it reliably?
Commercial challenge → Will biotech actually adopt this?
But these are execution challenges, not science ones. We’ll have to see how the team solves them. For now, it’s a real company working on a real problem, with cool tech!
If you made it this far, thank you! Would you store your DNA at room temperature? Are you doing it already? Do you like this format? Reply and let me know!
P.S: Know someone interested in Deep tech and Biotech? Share it with them!